The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
|Articles|April 1, 2004
Looking outside of the box: Spot melanoma in the 'wrong' places
La Jolla, Calif. - Melanoma can show up in unexpected places - and unlike most skin cancers, these may have little or no relationship to sun exposure. Dermatologists should be aware of these sites, how to diagnose and treat them, and when to refer patients to specialists. That was the subject of a presentation titled "Melanoma in All the Wrong Places" given at the Melanoma 2004: 14th Annual Cutaneous Malignancy Update.
Advertisement
Advertisement
Related to this article
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.
Advertisement
Advertisement
Trending on Dermatology Times
1
Galderma to Acquire ZO Skin Health for $1.5 Billion
2
Q&A: Falk G. Bechara, MD, on Long-Term Tunnel Control and Structural Damage in HS
3
Chronic Hand Eczema Linked to Lost Productivity and Lower Quality of Life
4
Exosome Progress and Remibrutinib Label Expansion
5